rewrite a written project

profilesandOG
ERADICATINGTHROMBUSINPATIENTSSUPPORTEDBYLEFTVENTRICULARASSISTDEVICES.docx

ERADICATING THROMBUS IN PATIENTS SUPPORTED BY LEFT VENTRICULAR ASSIST DEVICES

BACKGROUND AND CLINICAL SIGNIFICANCE

The Epidemiology of Cardiac Failure and the Left Ventricular Assist Device

Cardiac failure has become immensely prevalent in recent years. The incidence is now so high, that the condition is considered an emerging epidemic. More than 5.8 million citizens of the United States and 23 million from around the world suffer from heart failure (reference 1). The cost to treat this global health issue is astronomical, costing 39 billion dollars annually in the USA alone. Unfortunately, treatments are not always successful. The mortality rate of heart failure exceeds that of most cancers (reference 2). Causes of cardiac failure include myocardial ischemia, hypertension, cardiomyopathy, pulmonary hypertension, and congenital heart disease (reference 3). These causes are becoming increasingly pervasive due to health-care lengthened lifespan and widespread obesity.

The ideal solution for cardiac failure is organ transplant. A patient undergoing this treatment would have their heart replaced with a donor heart and take immunosuppressant medication for the rest of their life. Unfortunately, the supply of organs is never large enough to accommodate all patients with heart failure. Many patients die on the waiting list to receive one of these hearts. A temporary solution to this problem is implantation of a left ventricular assist device (LVAD). An LVAD is a titanium alloy (Ti-6Al-4V: 4 percent Vanadium and 6 percent Aluminum) centrifugal pump that is inserted into the apex of the heart. Blood flows from the left ventricle into the device where it is then shuttled through a polytetrafluoroethylene fabric outflow graft and into the aorta. By directing blood flow in this way, the LVAD effectively bypasses the left ventricle. The impeller within the pump (also made with Ti-6Al-4V) is magnetically levitated to reduce wear and hemolysis. The speed at which it rotates can be modulated with respect to a patient’s remaining heart function.

Figure 1: Structure, Mechanism, and Placement of an LVAD. (reference 4)

BIOCOMPATIBILITY PROBLEM

Thrombus and Associated Issues with the LVAD

The LVAD is an efficacious device but it is not without its complications. Problems ranging from infection to right ventricular failure prevent it from being an irreprehensible, long-term solution. One of the most medically dangerous and costly events that can occur is a pump thrombus. Because the blood contacting surface of the pump permits protein adsorption, blood clots can form and hinder pump’s function. Thrombi can slow or even stop the impeller from spinning entirely. If embolisms are pushed out of the pump, a life-threatening heart attack or stroke can occur. Pump thrombus occurs at a rate of 0.08 events per patient year, which is considered a clinically significant adverse event (reference 7).

There is no simple solution for pump thrombosis. The clot is either left in place or the patient’s old pump is explanted and replaced with a new one. The replacement surgery is long and dangerous: far from ideal for a patient with a failing heart. To prevent this outcome, all LVAD recipients are required to take anticoagulant drugs instead of immunosuppressants for the duration of the implant’s residence inside their chest. Anticoagulants cause many bleeding complications. Frequent trips to the ER for ailments as simple as epistaxis may be necessary.

The incidence of pump-clogging thrombus has increased with the shrinkage of pumps. Continuous flow LVADs have become smaller over time and were engineered to be this way. Smaller pumps are less invasive. They provide less surface area for protein adsorption and smaller incisions for surgery. They do not compete for space in the body as much as their larger pneumatic total artificial cousins and 2001 continuous flow grandparents. Unfortunately, they also are more easily clogged. A thrombus that would cause no significant change in function for a larger LVAD would cause a complete halt in a smaller one (reference 8). Pump thrombi are often more serious in modern LVADs and may require more aggressive intervention.

Mechanism of Pump Thrombus

The genesis of pump thrombus begins with an incision. As the surgery continues and the device is inserted, thousands of small blood vessels are ruptured. Bleeding occurs, and thereby allows protein to be introduced to the surface of the implant. Many materials used for implants are relatively hydrophobic. Proteins, therefore, find it more energetically favorable to allow their hydrophobic cores interaction with the foreign surface and their hydrophilic shells interaction with the surrounding water. Under these conditions, the proteins flatten on the surface and denature, triggering an inflammatory response. Complement proteins bind to the denatured proteins and activate the clotting cascade. Eventually, thrombosis is seen. This process is natural and occurs in healthy individuals. In patients with organ failure, the body’s heightened inflammatory state accelerates and exacerbates the clotting cascade: thrombosis is more likely.

Pump thrombosis can also be exacerbated by the specific properties of the foreign materials placed in the body. Ti-6Al-4V is a promising material choice under some conditions, as it creates a natural oxide layer. This oxide layer allows the titanium immunity from thrombosis: the surface becomes hydrophilic and renders protein adsorption unfavorable. Resistance to thrombus has been shown to be largely proportional to the breadth of the oxide layer. In vitro, this can be easily controlled by creating a consistent immersion fluid. Unfortunately, in vivo, there is no way to ensure that the oxide layer will be thick or consistent enough to remain inert (reference 9). Without the oxide layer, the titanium alloy transitions from benign, to thombogenically favorable.

Figure 2: Variable Oxide Layer with Respect to Surrounding Fluid. (reference 12) Figure 3: SEM Micrograph of Ti-6Al-4V and Nanotubules of Oxide Layer. (reference 13)

A pump thrombus can form in various places. There are three main locations that clots tend to develop: the inflow cannula, the impeller and housing, and the outflow graft. Clots on the inflow cannula occur inside the left ventricle and obstruct the entrance to the pump. They often become quite large (see figure 3). Clots inside of the pump itself tend to form on the sharp angles and depressions of the impeller. Mechanical bearings on pumps that contain them also provide a hospitable landscape for clots. These coagulates can thrombose the entire pump. Most clots on centrifugal pumps tend to be laminar fibrins. Alternatively, clots on axial pumps tend to be globular. Thrombosis commonly looks quite different in the outflow graft, as the blood contacting material is made from GoreTex® rather than titanium alloy. In fact, post-pump thrombosis resembles arterial stenosis quite closely. Coagulated blood builds on the graft walls and eventually slows or occludes blood flow. The treatment for this almost identical to stenosis in a blood vessel: a stent is placed (reference 10). These stents possess all of the biocompatibility faults that their ‘angio’ cousins do.

Figure 4: Types of Pump Thrombus. (reference 5) Figure 5: Photo of a Pump Thrombus (reference 6)

While thrombus significantly alters the function of the VAD pump, all clots can become more dangerous if they dislodge. Embolic stroke and heart attacks occur in almost 1/3 of all patients (reference 11) and can cause significant mortality if not recognized early on.

DESIGN SOLUTION

Superomniphobic Coating Applied to Only the Inside of the Pump

The solution to thrombus in left ventricular assist devices must not diminish functionality of the pump. To truly ensure this, our team did not alter the physical design of the LVAD at all. Instead we plan treat the blood contacting surfaces such that they are no longer hemophilic. A previously proposed solution to the problem has been to coat the surface of titanium with superomniphobic material. Hydrophobicity is unfavorable due to its encouragement of protein binding, but omniphobicity discourages binding and adsorption of any kind. Superomniphobic material repels almost all liquids; it is both hydrophobic and hemophobic. Unfortunately, universally repellant materials also discourage tissue growth. Physicians and surgeons desire tissue ingrowth on the outside of the device in order to secure it. Tissue contacting portions of the LVAD are sintered for this very reason. Ideally, cells anchor the device to the heart so that no slippage occurs. Omniphobic coatings thereby create another problem in place of the problem they solve.

Our team’s design will not be subject to the problems associated with a complete coating. It includes an omniphobic coating on only the inside of the device, while leaving the outside as raw titanium alloy. With this design, the inside of the pump will be theoretically immune to thrombus. The outside of the pump will maintain its normal sintering to promote tissue ingrowth. No further ingrowth promotors will be added, as the pump is secured to the heart with a suture ring.

The most effective superomniphobic material found so far has been fluorinated nanotubes. These carbon nanotubes are affixed to a titanium surface at a 90 degree angle. They are then treated with F2 at a high temperature to become fluorinated. Single-walled nanotubes tend to be more expensive than multi-walled nanotubes.

Figure 6: Blood, Oil, and Water on Coated Ti-6Al-4V (reference 14) Figure 7: SEM Micrograph Fluorinated Carbon Nanotubes (reference 15)

The fluorinated nanotubes will be affixed to the inner walls of the inflow cannula. They will extend until the cessation of curvature on the outer lip. The area beyond this boundary will not be coated. The inside of the pump housing will be coated along with all surfaces of the impeller. Extra coating will be added to the sharp corners of the impeller, as many blood clots form preferentially in these locations. The outflow graft will also be coated in fluorinated nanotubes. This area may require a different method of tube fixation, as it is made of GoreTex® rather than titanium. The outflow graft coating will extend to the edge of the tube. Anticoagulant releasing sutures could prevent the boundary from clotting if warfarin is not an option.

JUSTIFICATION AND RATIONALE

Superomniphobic Coatings

Use of superomniphobic material for the coating of the left ventricular assist device was favorable over other hydrophobic options. This is because repulsion of protein along with water is critical for the success of the coating. Hydrophobicity can often be less favorable than hydrophilicity due to its inherent ability to attract the inner cores of protein. Therefore, any alternative methods of coating the left ventricular device would maintain omniphobicity. Repulsion of all blood occupying the pump at a given time could do more than stop protein adsorption. It could limit shear stress and possibly decrease the incidence of gastrointestinal bleeds. While fluorinated nanotubes are an attractive selection for a coating, there are alternatives that could potentially accomplish the same task. Polydimethylsiloxane polymers also exhibit omniphobic properties and may provide a more cost-effective solution. Application of the polymers may also be much easier than fixation of nanotubes. The surface of the titanium would theoretically need only purification and plasma etching. The coating could then be applied by dipping the device. Polydimethylsiloxane can maintain its properties for up to a year and is very cheap (reference 16). Another option is X-SLIPS, a waxy porous coating inspired by plants. X-SLIPS is also applied to surfaces by dipping and can be bound to many kinds of metals, plastics, glasses, and ceramics. It also boasts the added benefit of thermal self-repair. Under high heat stimulation, damage sustained by the coating can be remedied without physical or surgical intervention (reference 17). Thermal self-repair applies to even large areas of either physical or chemical damage. This property is beneficial, as explantation to repair or replace a device can be dangerous for the patient.

Figure 8: Polydimethylsiloxane Polymer Diagram (reference 16) Figure 9: X-SLIPS Origin and Function Flowchart (reference 17)

The main danger with these alternative coatings is the possibility of leaching. The surface could become eroded over time and toxic chemicals released into the bloodstream. All coatings would require in situ testing to determine chemical stability under bodily conditions. Currently, fluorinated nanotubes are considered the most eligible for use in implants. Their structure is inert and relatively durable. They also create the largest visually perceptible contact angle, which suggests that they are the most universally repellent. While they are the most expensive option, they would be applied to only the inside of the pump. Lesser surface area may offset large costs associated with this coating.

Cost Analysis

As mentioned previously, the cost of coating a left ventricular assist device will be largely determined by whether or not single-walled nanotubes are necessary for clotting immunity. The price difference between single-walled nanotubes and multi-walled nanotubes is very significant. Multi-walled nanotubes range from 2-30 dollars per gram whereas single walled nanotubes range from 156.25 to 300 dollars per gram: about a 90 percent difference (reference 18). Price of carbon fluorinated nanotubes may also change based on tube length and purity. Most tubes available for purchase currently have a purity of 99.5 percent. This level of purity may be excessive, or it may be lacking. Our blood coagulation tests will determine this. Tube length also varies significantly in most products. Some range from 2-10 microns. Others vary more. There is possibly an ideal length for optimal hemophobicity, which may require more expensive reagents. Unavailability of uniform tubes may necessitate production of tubes in the manufacturing process rather than purchase. A standardized procedure for acquiring and coating the LVADs with tubes on an industrial scale may decrease costs significantly (such that the price difference between coated and non-coated devices is negligible).

PROPOSED VERIFICATION TESTING

Mechanical Wear Testing

One of the most critical tests to perform on the nanotubes is mechanical testing. Many patients retain their devices for 10 years or more. Reoperation for replacement of worn parts is often not possible, as most LVAD recipients are in their final years of life. The tubes must maintain their position and endure constant fluid movement across their surfaces for years at a time. To ensure that no erosion occurs, a coated left ventricular assist device will be placed in different buckets of corrosive material and allowed to run for an extended period of time. At least one of the testing buckets will contain real or synthetic blood. Examination of the surface by scanning electron microscopy will occur at the conclusion of the mechanical tests. Length, thickness and topography will be analyzed on the coated surfaces of the device. The media contained in each bucket will be analyzed for trace amounts of nanotube.

Cytotoxicity Testing

Our device will be tested for cytotoxicity. Small samples of titanium will be coated in carbon fluorinated nanotubes and placed in cell culture. Cells cultured in the presence of the titanium may include blood cells, cardiac cells, human embryonic kidney cells, fibroblasts, neurons, and E. coli. Cultures will be studied and analyzed for slowed growth, inhibited cellular processes, and apoptosis. In addition to direct contact, a MEM elution assay will be performed to exaggerate the conditions found in the body. 0% relative cytotoxicity must be achieved before implantation, as long-term cell death could be devastating.

Implantation Testing

To truly test the long-term viability of our coating, implant testing is necessary. The devices will be implanted into pigs. These implants will be left in for 1.5 years, as most thrombus events occur in the first year. Monthly blood samples will be extracted from the animals to test for trace amounts of fluorine. At the conclusion of the testing period, the implants will be extracted and analyzed in a similar fashion to our mechanical wear tests. Any clots will be recorded.

Mechanical Coagulation Testing

The final tests that must be performed on the carbon fluorinated nanotubes are coagulation tests. The most relevant clotting test for this situation is a mechanical test. Blood is poured into a cup. A second cup is nested inside of the first, effectively sandwiching the blood. A force sensing device then spins one cup while leaving the other stationary. As the blood clots over time, turning requires more force. This force is documented and used to analyze how quickly coagulation occurs. We will use a similar device, however our cups will be coated in carbon fluorinated nanotubes. No blood clotting should be visible on the sides of the cups. The force required to rotate should remain constant for an extended period of time.

Sterilization

Because left ventricular assist devices are implanted in one of the most vulnerable parts of the human body, a rigorous sterilization process is critical. We will run sterilization tests on our devices. Similarly to the mechanical wear test, we will treat the coated LVAD to standard sterile procedures and then view the surface using scanning electron microscopy. Any wear or denaturation inflicted on the tubes must be addressed. High temperatures can temporarily rearrange unbound carbon nanotubes, however the properties of bound carbon nanotubes have not been entirely determined yet. Fortunately, sterile procedures can be adapted. If high temperatures are damaging, chemical sterilization may also be feasible. Surface observation will be performed after all possible protocols.

http://circres.ahajournals.org/content/113/6/646

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3033496/

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3096504/

https://ajkdblog.org/2018/01/30/left-ventricular-assist-devices-and-kidney-function-an-overview-for-nephrologists/

https://www.sciencedirect.com/science/article/pii/S0735109716326997

https://www.sciencedirect.com/science/article/pii/S1016731515001530

https://www.sciencedirect.com/science/article/pii/S1053249813015386

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4229473/

http://www.jtcvsonline.org/article/S0022-5223(14)01989-8/fulltext

https://journals.lww.com/asaiojournal/Fulltext/2017/01000/Endovascular_Stenting_of_a_LVAD_Outflow_Graft.21.aspx

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4500598/

http://www.implanti.mk/titanium/

https://www.researchgate.net/figure/SEM-micrographs-of-Ti6Al4V-surface-anodized-in-1M-H-3-PO-4-05-wt-HF-U20-V-2_fig5_311333807

https://phys.org/news/2017-01-blood-repellent-materials-approach-medical-implants.html

https://source.colostate.edu/blood-repellent-materials-new-approach-medical-implants/

https://www.chemistryworld.com/news/super-repellent-coating-ready-in-seconds/9229.article

https://pubs.acs.org/doi/abs/10.1021/acsami.6b00194

https://www.cheaptubes.com/product-category/functionalized-carbon-nanotubes/fluorine-functionalized-carbon-nanotubes/

https://www.fda.gov/MedicalDevices/Safety/AlertsandNotices/ucm457327.htm